Baxter Recalls Two Sodium Chloride Lots Over Fiberglass

Fiberglass particulate contamination in a parenteral IV solution is among the higher-severity defect categories under USP <788> and 21 CFR Part 211.68, and Baxter International's voluntary recall of two lots of 0.9% Sodium Chloride Injection, USP, 500 mL VIAFLEX Plastic Containers puts container closure integrity and in-process filtration controls squarely under scrutiny. The company announced the action on August 25, 2026; FDA published the notice the following day.

The affected lots, Y49552 and Y49552A, both carrying an expiration date of October 31, 2027, were distributed between July 31 and August 3, 2026, reaching healthcare providers and distributors across fourteen states, including Florida, Illinois, New York, and Texas. Product code 2B1323Q covers the 500 mL VIAFLEX container, packaged 24 units per case, under NDC 0338-0049-03.

The clinical risk profile is serious. Intravenous administration of a solution containing fiberglass particulates carries documented potential for vascular occlusion, pulmonary embolism, permanent organ damage, and death. Secondary risks include local vein irritation, inflammatory response, aggravation of existing infections, and allergic reactions. As of the announcement date, Baxter had received no adverse event reports linked to these lots.

For QA directors and plant heads at IV solution manufacturers, the contamination mode warrants a focused internal review. Fiberglass particulates in a VIAFLEX container point toward potential degradation or breach at the container-component interface, areas governed by container closure system qualification under ICH Q10 and inspected against the particulate matter limits defined in USP <788> (sub-visible) and USP <790> (visible). Facilities using flexible plastic container systems should confirm that incoming component inspection, in-process particulate monitoring, and 100% visual inspection protocols are operating within validated parameters.

Baxter is notifying affected customers directly by email with return instructions. Facilities holding implicated units are directed to discontinue use immediately and follow their site-specific returns process. Baxter's Healthcare Center for Service is available at 888-229-0001, Monday through Friday, 7:00 a.m. to 6:00 p.m. Central Time. Adverse events or quality complaints may be submitted to FDA's MedWatch program online at www.fda.gov/medwatch/report.htm.

The breadth of the distribution footprint, fourteen states over a four-day window, will determine the complexity of the field correction effort and may inform FDA's subsequent inspection posture at the originating facility.

Source: FDA Recalls, Market Withdrawals & Safety Alerts via FDA.gov, August 26, 2026. Company announcement dated August 25, 2026.